文献速递神经肿瘤

CBTRUS统计报告:2015-2019年美国诊断的原发性脑及其他中枢神经系统肿瘤

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.
PubMed 文献 · Neuro Oncol · 2022-01-01

美国脑肿瘤注册中心(CBTRUS)联合CDC和NCI,基于全美人群报告2015-2019年原发性脑及其他CNS肿瘤数据。全部恶性肿瘤及非恶性肿瘤年均年龄调整发病率为24.71/10万(恶性7.02,非恶性17.69),女性高于男性(27.62 vs 21.60/10万)。胶质母细胞瘤占所有恶性肿瘤的50.1%,脑膜瘤占所有非恶性肿瘤的55.4%。

要点

  • 全部脑及其他CNS肿瘤AAAIR为24.71/10万,女性27.62高于男性21.60/10万。
  • 胶质母细胞瘤占全部肿瘤14.2%、占恶性肿瘤50.1%;脑膜瘤占全部肿瘤39.7%、占非恶性肿瘤55.4%。
  • 恶性脑及其他CNS肿瘤5年相对生存率为35.7%,非恶性肿瘤为91.8%。

核心结论

  • 本报告提供了美国全人群原发性脑及其他CNS肿瘤的最新发病、死亡和生存数据,在完整性和准确性上取代既往所有报告。

研究设计与样本

  • 美国脑肿瘤注册中心(CBTRUS)与疾病控制与预防中心及美国国家癌症研究所合作开展,是专注于美国原发性脑及其他CNS肿瘤的最大人群登记,覆盖全美人口。
  • 所有率均按2000年美国标准人口进行年龄调整,并以每10万人口表示。

主要发现

  • 全部恶性及非恶性脑及其他CNS肿瘤的年均年龄调整发病率(AAAIR)为24.71/10万(恶性AAAIR=7.02,非恶性AAAIR=17.69)。
  • 总体发病率女性高于男性(27.62 vs 21.60/10万),非西班牙裔高于西班牙裔(25.09 vs 22.95/10万)。
  • 最常见的恶性组织病理学为胶质母细胞瘤(占全部肿瘤14.2%、占全部恶性肿瘤50.1%),最常见的非恶性组织病理学为脑膜瘤(占全部肿瘤39.7%、占全部非恶性肿瘤55.4%)。
  • 胶质母细胞瘤在男性中更常见,脑膜瘤在女性中更常见;儿童和青少年(0-19岁)全部原发性脑及其他CNS肿瘤发病率为6.20/10万。
  • 2015-2019年间归因于恶性脑及其他CNS肿瘤的死亡为84,264例,年均死亡率为4.41/10万,年均死亡16,853例。

关键数值与推荐

  • 预计2022年美国人群中将诊断93,470例新发恶性及非恶性脑及其他CNS肿瘤(恶性26,670例,非恶性66,806例)。
  • 恶性脑及其他CNS肿瘤诊断后5年相对生存率为35.7%,非恶性脑及其他CNS肿瘤为91.8%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.71 per 100,000 population (malignant AAAIR=7.02 and non-malignant AAAIR=17.69). This overall rate was higher in females compared to males (27.62 versus 21.60 per 100,000) and non-Hispanic persons compared to Hispanic persons (25.09 versus 22.95 per 100,000). The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (14.2% of all tumors and 50.1% of all malignant tumors), and the most common non-malignant histopathology was meningioma (39.7% of all tumors and 55.4% of all non-malignant tumors). Glioblastoma was more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.20 per 100,000 population. An estimated 93,470 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US population in 2022 (26,670 malignant and 66,806 non-malignant). There were 84,264 deaths attributed to malignant brain and other CNS tumors between 2015 and 2019. This represents an average annual mortality rate of 4.41 per 100,000 population and an average of 16,853 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.7%, while for non-malignant brain and other CNS tumors the five-year relative survival rate was 91.8%.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ostrom QT, Price M, Neff C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. Neuro Oncol. 2022. PMID: 36196752. doi:10.1093/neuonc/noac202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。